Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 46 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

39%

18 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 4
11(28.9%)
Phase 2
10(26.3%)
N/A
8(21.1%)
Phase 3
7(18.4%)
Phase 1
2(5.3%)
38Total
Phase 4(11)
Phase 2(10)
N/A(8)
Phase 3(7)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (46)

Showing 20 of 46 trials
NCT07709585Phase 2Not Yet Recruiting

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Role: collaborator

NCT07615309Enrolling By Invitation

To Evaluate the Clinical Efficacy and Safety of Omadacycline in the Treatment of Mycobacterium Abscessus Infection.

Role: lead

NCT07607288Enrolling By Invitation

Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions.

Role: lead

NCT07396701Phase 4Not Yet Recruiting

Chinese Adaptive Randomised Pneumonia Trial With Respiratory Failure

Role: collaborator

NCT07372781Phase 2Enrolling By Invitation

Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease

Role: lead

NCT07338396Not Yet Recruiting

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients

Role: collaborator

NCT07295938Phase 2Recruiting

TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease

Role: collaborator

NCT07268664Phase 3Not Yet Recruiting

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BLMZ Chinese Cohort

Role: lead

NCT07213765Phase 4Recruiting

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

Role: collaborator

NCT07174076Phase 4Recruiting

Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease

Role: collaborator

NCT06649721Phase 3Active Not Recruiting

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort

Role: collaborator

NCT06081361Phase 3Active Not Recruiting

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort

Role: lead

NCT06811792Completed

Intrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes

Role: lead

NCT06811025Phase 1Enrolling By Invitation

Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis

Role: lead

NCT06811012Phase 1Enrolling By Invitation

Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis

Role: lead

NCT06809413Phase 2Enrolling By Invitation

Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease

Role: lead

NCT06764368Phase 2Not Yet Recruiting

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

Role: lead

NCT05922449Not ApplicableCompleted

Using Thoracic Paravertebral Block for Perioperative Lung Preservation During VATS Pulmonary Surgery

Role: collaborator

NCT06476210Phase 4Recruiting

The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Role: lead

NCT06403943Phase 4Recruiting

Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

Role: lead